Develops boron-based small-molecule drug candidates for patients with blood disorders, infectious diseases and cancer.
10-K for FY2025, filed Mar 17, 2026We are a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived…View ↗
Our Research and Development InitiativesView ↗
We are pursuing a number of oncology targets where we believe our boron chemistry may offer a competitive advantage in terms of…View ↗
Broader disease focus
The earlier report centered on infectious-disease treatments, especially epetraborole for MAC lung disease. The latest report describes development and research across hematologic diseases, infectious diseases and oncology.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 17, 2026
Beyond MAC lung disease
The earlier report focused epetraborole development on treatment-refractory MAC lung disease and planned expansion to other NTM infections. The latest report also describes epetraborole development for polycythemia vera and M. abscessus lung disease, alongside a separate Chagas disease candidate.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 17, 2026AN2 Therapeutics, Inc. is a Delaware corporation incorporated on February 24, 2017. We launched operations in November 2019. We are a…View ↗
Treatment-refractory MAC lung disease: We are initially focused on advancing our first product candidate, epetraborole, to…View ↗
M. abscessus lung disease: We are currently conducting nonclinical studies as part of a dose selection study to support clinical…View ↗
In March 2026, we announced our plan to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in…View ↗
In December 2025, the U.S. Food and Drug Administration (“FDA”) cleared an Investigational New Drug Application (“IND”) to proceed with a…View ↗
In August 2025, as part of our Chagas disease clinical development program, we commenced our Phase 1 first-in-human trial of oral…View ↗
Loading...